GENFIT Stock Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 82.45M 88.31M 121M | Sales 2025 * | 48.61M 52.07M 71.21M | Capitalization | 173M 185M 253M |
---|---|---|---|---|---|
Net income 2024 * | 19M 20.35M 27.83M | Net income 2025 * | -21M -22.49M -30.76M | EV / Sales 2024 * | 1.99 x |
Net cash position 2024 * | 8.71M 9.33M 12.76M | Net cash position 2025 * | 44.9M 48.09M 65.77M | EV / Sales 2025 * | 2.63 x |
P/E ratio 2024 * |
13.6
x | P/E ratio 2025 * |
-36.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.86% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |